Home › Takeda Licenses Rights To Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology
 

Keywords :   


Takeda Licenses Rights To Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology

2015-04-01 08:41:48| drugdiscoveryonline Home Page

Takeda Pharmaceutical Company Limited and ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology, recently announced that Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents – to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets

Tags: rights technology licenses conjugate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
12.06U.S. House of Representatives Approves WIPPES Legislation
12.06Michael Maginnis Named Regional Sales Manager at JNS-SmithChem
12.06Airport bosses criticise sudden liquids U-turn
12.06AkzoNobel Opens World-first Testing Facility for Wind Turbine Blades
12.06US inflation cools as interest rate decision looms
12.06Certified Waste Solutions Acquires Waste Control
12.06Atlantic Tropical Weather Outlook
12.06Eastern North Pacific Tropical Weather Outlook
More »